MX2020002725A - Nueva formulacion de acido gamma-aminobutirico. - Google Patents

Nueva formulacion de acido gamma-aminobutirico.

Info

Publication number
MX2020002725A
MX2020002725A MX2020002725A MX2020002725A MX2020002725A MX 2020002725 A MX2020002725 A MX 2020002725A MX 2020002725 A MX2020002725 A MX 2020002725A MX 2020002725 A MX2020002725 A MX 2020002725A MX 2020002725 A MX2020002725 A MX 2020002725A
Authority
MX
Mexico
Prior art keywords
gamma
aminobutyric acid
dosage form
new formulation
gaba
Prior art date
Application number
MX2020002725A
Other languages
English (en)
Inventor
Anton Lindqvist
Ulf Hannelius
Original Assignee
Diamyd Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab
Publication of MX2020002725A publication Critical patent/MX2020002725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a una forma de dosificación oral que comprende ácido gamma-aminobutírico (GABA) y los excipientes farmacéuticamente aceptables, en la que el 100% del GABA se libera dentro de 0.25-5 horas en 0.01 M HCl a 37 °C en un aparato de disolución USP 2. La invención se refiere además a formas de dosificación específicas, métodos para el tratamiento de enfermedades autoinmunes con la forma de dosificación, así como el uso de la forma de dosificación en tales métodos.
MX2020002725A 2017-09-19 2018-08-24 Nueva formulacion de acido gamma-aminobutirico. MX2020002725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1751159 2017-09-19
PCT/SE2018/050855 WO2019059822A1 (en) 2017-09-19 2018-08-24 NOVEL FORMULATION OF GAMMA-AMINOBUTYRIC ACID

Publications (1)

Publication Number Publication Date
MX2020002725A true MX2020002725A (es) 2020-11-06

Family

ID=65811513

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002725A MX2020002725A (es) 2017-09-19 2018-08-24 Nueva formulacion de acido gamma-aminobutirico.
MX2023002649A MX2023002649A (es) 2017-09-19 2020-03-11 Nueva formulacion de acido gamma-aminobutirico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002649A MX2023002649A (es) 2017-09-19 2020-03-11 Nueva formulacion de acido gamma-aminobutirico.

Country Status (7)

Country Link
US (1) US11638701B2 (es)
EP (1) EP3684349A4 (es)
JP (1) JP7225221B2 (es)
CN (1) CN111386108A (es)
CA (1) CA3074261A1 (es)
MX (2) MX2020002725A (es)
WO (1) WO2019059822A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115651054B (zh) * 2019-01-08 2024-06-21 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CN112843002B (zh) * 2021-04-06 2022-12-13 南京纽邦生物科技有限公司 一种γ-氨基丁酸口服缓释干混悬剂及其制备方法
CN113080436B (zh) * 2021-04-08 2024-03-01 南京纽邦生物科技有限公司 γ-氨基丁酸干混悬剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003088335A (ja) 2001-09-14 2003-03-25 Pharmafoods Kenkyusho:Kk 排尿機能改善用食品組成物及びそれを含有する飲食品
US20050226927A1 (en) 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20050220864A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP2008074734A (ja) 2006-09-20 2008-04-03 Unitika Ltd インスリン抵抗性改善剤
US9463174B2 (en) 2008-12-19 2016-10-11 Qinghua Wang Pharmaceutical composition for the treatment of type-1 diabetes
JP5479754B2 (ja) 2009-02-19 2014-04-23 キユーピー株式会社 粉末状組成物および錠剤、ならびにγ−アミノ酪酸の褐変防止方法および褐変防止剤
CN102106839A (zh) * 2009-12-23 2011-06-29 北京科信必成医药科技发展有限公司 一种阿普唑仑缓释制剂及其制备方法
CN103054044B (zh) * 2012-12-26 2014-09-03 北京康比特体育科技股份有限公司 一种改善睡眠的保健食品组合物
CN106606495A (zh) * 2015-10-27 2017-05-03 四川海思科制药有限公司 一种普瑞巴林缓释片药物组合物及其制备方法
AU2018292531A1 (en) * 2017-06-27 2020-02-13 Harmonix, Llc Time release sleep aid system

Also Published As

Publication number Publication date
US20210137867A1 (en) 2021-05-13
CA3074261A1 (en) 2019-03-28
MX2023002649A (es) 2023-03-22
CN111386108A (zh) 2020-07-07
WO2019059822A1 (en) 2019-03-28
EP3684349A4 (en) 2021-06-09
JP7225221B2 (ja) 2023-02-20
JP2020534302A (ja) 2020-11-26
US11638701B2 (en) 2023-05-02
EP3684349A1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MX2021002321A (es) Nuevos metodos.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
PH12021551635A1 (en) Hexone glucokinase inhibitor and use thereof
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
MY198587A (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
ZA202000028B (en) Use of vibegron to treat overactive bladder
NZ737948A (en) Orodispersible dosage unit containing an estetrol component
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
PH12020500032A1 (en) Isotretinoin oral-mucosal fromulations and methods for using same
WO2016168553A8 (en) Deuterated obeticholic acid
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
JP2016505050A5 (es)
MY193963A (en) Composition for treating joint diseases and kit containing same
NZ751972A (en) Treatment of prurigo nodularis
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX2022012693A (es) Composicion que comprende metilfolato.
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
MX2013009849A (es) Capsula con contenido liquido con un antiinflamatorio.